drugset / Trial / NCT07539454
Nirogacestat in Patients With Kaposi Sarcoma
Phase 2
Not yet recruiting
28 enrolled
AIDS Malignancy Consortium
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well nirogacestat works in treating patients with skin Kaposi sarcoma (KS). Several anti-cancer drugs work well in treating KS, but there is no treatment that cures KS. Nirogacestat binds to a protein called gamma secretase, which blocks the activation of other proteins called Notch receptors. Blocking these proteins may help keep tumor cells from growing and may kill them. Nirogacestat is a type of gamma secretase inhibitor. Nirogacestat may be effective in shrinking the size of KS lesions and reducing the spread of lesions.
Timeline
- Start
- 2026-09-17
- Primary completion
- 2030-02-17
- Completion
- 2030-02-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nirogacestat | Small molecule | — | Oral |